{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:40:15Z","timestamp":1758552015173,"version":"3.44.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-18076-0","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:33:59Z","timestamp":1754584439000},"page":"7262-7263","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Surgical Conversion in Borderline Resectable Cholangiocarcinoma"],"prefix":"10.1245","volume":"32","author":[{"given":"Yawen","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Starlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"18076_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. ABC-02 Trial Investigators. Cisplatin plus emcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med."},{"key":"18076_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/COC.0000000000000861","volume":"44","author":"LE Nooijen","year":"2021","unstructured":"Nooijen LE, Franken LC, Belkouz A, OuladAbdennabi I, Besselink MG, Busch OR, et al. Efficacy and safety of gemcitabine plus cisplatin as potential preoperative chemotherapy in locally advanced intrahepatic, perihilar, and mid-cholangiocarcinoma: a retrospective cohort study. Am J Clin Oncol. 2021;44:526\u201332. https:\/\/doi.org\/10.1097\/COC.0000000000000861. (PMID: 34469345).","journal-title":"Am J Clin Oncol."},{"key":"18076_CR3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17991-6","author":"Y Dong","year":"2025","unstructured":"Dong Y, Santol J, Podrascanin V, et al. Conversion to resection after neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel in borderline resectable CCA: a real-world exploratory analysis. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17991-6.","journal-title":"Ann Surg Oncol."},{"key":"18076_CR4","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30:6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","journal-title":"Ann Surg Oncol."},{"key":"18076_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17776-x","author":"J Kawashima","year":"2025","unstructured":"Kawashima J, Akabane M, Woldesenbet S, et al. Oncological resectability criteria for intrahepatic cholangiocarcinoma: a preoperative framework for multidisciplinary management. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17776-x.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18076-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18076-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:05:28Z","timestamp":1758549928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18076-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["18076"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18076-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}